WHAT IS CLAIMED IS:

1. An isolated anti-Bv8 antibody comprising a variable domain comprising the following six hypervariable region (HVR) sequences:

(i) HVR-L1 comprising KASQSX$_1$X$_2$YX$_3$X$_4$X$_5$SYMN, wherein X$_1$ is L or V; X$_2$ is D; X$_3$ is S or Y; X$_4$ is G or H; and X$_5$ is D or Y;

(ii) HVR-L2 comprising AASX$_1$X$_2$EX$_3$, wherein X$_1$ is N; X$_2$ is L or R; and X$_3$ is S;

(iii) HVR-L3 comprising QQINEDPFT;

(iv) HVR-H1 comprising GYX$_1$X$_2$X$_3$X$_4$YDMH, wherein X$_1$ is S; X$_2$ is F or L; X$_3$ is T; X$_4$ is D or N;

(v) HVR-H2 comprising YIX$_1$X$_2$YX$_3$GX$_4$TX$_5$YNQKFKG, wherein X$_1$ is H or S; X$_2$ is S; X$_3$ is S; X$_4$ is A or S; X$_5$ is L or T, and

(vi) HVR-H3 comprising DX$_1$NYGEAYAMDY, wherein X$_1$ is S,

or an antigen-binding fragment thereof.

2. The anti-Bv8 antibody of claim 1, wherein HVR-L1 comprises an amino acid sequence of SEQ ID NO: 61 or 91, HVR-L2 comprises an amino acid sequence of SEQ ID NO: 62 or 92, HVR-L3 comprises an amino acid sequence of SEQ ID NO: 63 or 93, HVR-H1 comprises an amino acid sequence of SEQ ID NO: 64 or 94, HVR-H2 comprises an amino acid sequence of SEQ ID NO: 65 or 95, and HVR-H3 comprises an amino acid sequence of SEQ ID NOs: 66 or 96, or an antigen-binding fragment thereof.

3. The anti-Bv8 antibody of claim 2, wherein the antibody comprises:

(1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:61;

(2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:62;

(3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:63;

(4) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:64;

(5) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:65; and

(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:66,

or an antigen-binding fragment thereof.

4. The anti-Bv8 antibody of claim 3 comprising a light chain variable domain comprising SEQ ID NO: 7 and the heavy chain variable domain comprising SEQ ID NO: 8, or an antigen-binding fragment thereof.

5. The anti-Bv8 antibody of claim 2, wherein the antibody comprises:
(1) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:91;
(2) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:92;
(3) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:93;
(4) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:94;
(5) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:95; and
(6) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:96,
or an antigen-binding fragment thereof.

6. The anti-Bv8 antibody of claim 5 comprising a light chain variable domain comprising SEQ ID NO: 11 and the heavy chain variable domain comprising SEQ ID NO: 12, or an antigen-binding fragment thereof.

7. An isolated nucleic acid encoding the antibody or the antigen-binding fragment thereof of any one of claims 1-6.

8. A vector comprising the nucleic acid of claim 7.

9. A host cell comprising the vector of claim 8.

10. Use of an effective amount of an anti-Bv8 antibody of any one of claims 1-6, in the manufacture of a medicament for treating a tumor, a cancer, or a cell proliferative disorder.

11. The use of claim 10, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, renal cancer, glioblastoma, esophageal cancer, melanoma, bladder cancer, ovarian cancer, pancreatic cancer, and hepatocellular carcinoma.

12. The use of claim 11 wherein the cancer is breast cancer, colorectal cancer, lung cancer, renal cancer, ovarian cancer or glioblastoma.

13. The use of any of claims 10-12, further comprising use of an effective amount of a second medicament, wherein the anti-Bv8 antibody is the first medicament.

14. The use of claim 13, wherein the second medicament is an anti-VEGF antibody.

15. The use of claim 14, wherein the anti-VEGF antibody is bevacizumab.

16. The use of any of claims 10-15, further comprising use of an effective amount of a chemotherapeutic agent.

WHAT IS CLAIMED IS:

1. An anti-Bv8 antibody comprising a variable domain comprising at least one, two, three, four, five or six hypervariable region (HVR) sequences selected from the group consisting of:

(i) HVR-L1 comprising $KASQSX_1X_2YX_3X_4X_5SYMN$, wherein X_1 is L or V; X_2 is D or I; X_3 is D, F, G, S, W or Y; X_4 is A, G, H or V; and X_5 is D, E or Y;

(ii) HVR-L2 comprising $AASX_1X_2EX_3$, wherein X_1 is N or Y; X_2 is L or R; and X_3 is S or T;

(iii) HVR-L3 comprising QQINEDPFT;

(iv) HVR-H1 comprising $GYX_1X_2X_3X_4YDMH$, wherein X_1 is S or T; X_2 is F or L; X_3 is F, M, P, T or V; X_4 is D, E, H, I, or N;

(v) HVR-H2 comprising $YIX_1X_2YX_3GX_4T\ X_5YNQKFKG$, wherein X_1 is H, S or T; X_2 is C, S or T; X_3 is A, L, N, S or T; X_4 is A, E or S; X_5 is I, L, S or T, and

(vi) HVR-H3 comprising $DX_1NYGEAYAMDY$, wherein X_1 is G or S.

2. The anti-Bv8 antibody of claim 1 comprising a variable domain comprising the following six HVR sequences:

(i) HVR-L1 comprising $KASQSX_1X_2YX_3X_4X_5SYMN$, wherein X_1 is L or V; X_2 is D or I; X_3 is D, F, G, S, W or Y; X_4 is A, G, H or V; and X_5 is D, E or Y;

(ii) HVR-L2 comprising $AASX_1X_2EX_3$, wherein X_1 is N or Y; X_2 is L or R; and X_3 is S or T;

(iii) HVR-L3 comprising QQINEDPFT;

(iv) HVR-H1 comprising $GYX_1X_2X_3X_4YDMH$, wherein X_1 is S or T; X_2 is F or L; X_3 is F, M, P, T or V; X_4 is D, E, H, I, or N;

(v) HVR-H2 comprising $YIX_1X_2YX_3GX_4T\ X_5YNQKFKG$, wherein X_1 is H, S or T; X_2 is C, S or T; X_3 is A, L, N, S or T; X_4 is A, E or S; X_5 is I, L, S or T, and

(vi) HVR-H3 comprising $DX_1NYGEAYAMDY$, wherein X_1 is G or S.

3. The anti-Bv8 antibody of claim 2, wherein HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:49, 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 139, 145 and 151, HVR-L2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 50, 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, 128, 134, 140, 146 and 152, HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 51, 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, 117, 123, 129, 135, 141, 147 and 153, HVR-H1

comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 52, 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, 136, 142, 148 and 154, HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 53, 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, 131, 137, 143, 149 and 155, and HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 54, 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150 and 156.

4. The anti-Bv8 antibody of claim 1 comprising a variable domain comprising at least one, two, three, four, five or six hypervariable region (HVR) sequences selected from the group consisting of:

(i) HVR-L1 comprising $KASQSX_1X_2YX_3X_4X_5SYMN$, wherein X_1 is L or V; X_2 is D or I; X_3 is F, G, S, W or Y; X_4 is A, G, H or V; and X_5 is D, E or Y;

(ii) HVR-L2 comprising $AASX_1X_2EX_3$, wherein X_1 is N or Y; X_2 is L or R; and X_3 is S or T;

(iii) HVR-L3 comprising QQINEDPFT;

(iv) HVR-H1 comprising $GYX_1X_2X_3X_4YDMH$, wherein X_1 is S or T; X_2 is F or L; X_3 is F, M, P, T or V; X_4 is D, E, H, I, or N;

(v) HVR-H2 comprising $YIX_1X_2YX_3GX_4T\ X_5YNQKFKG$, wherein X_1 is H, S or T; X_2 is S or T; X_3 is A, L, S or T; X_4 is A, E or S; X_5 is I, L, S or T, and

(vi) HVR-H3 comprising DSNYGEAYAMDY.

5. The anti-Bv8 antibody of claim 4 comprising a variable domain comprising the following six HVR sequences:

(i) HVR-L1 comprising $KASQSX_1X_2YX_3X_4X_5SYMN$, wherein X_1 is L or V; X_2 is D or I; X_3 is F, G, S, W or Y; X_4 is A, G, H or V; and X_5 is D, E or Y;

(ii) HVR-L2 comprising $AASX_1X_2EX_3$, wherein X_1 is N or Y; X_2 is L or R; and X_3 is S or T;

(iii) HVR-L3 comprising QQINEDPFT;

(iv) HVR-H1 comprising $GYX_1X_2X_3X_4YDMH$, wherein X_1 is S or T; X_2 is F or L; X_3 is F, M, P, T or V; X_4 is D, E, H, I, or N;

(v) HVR-H2 comprising $YIX_1X_2YX_3GX_4T\ X_5YNQKFKG$, wherein X_1 is H, S or T; X_2 is S or T; X_3 is A, L, S or T; X_4 is A, E or S; X_5 is I, L, S or T, and

(vi) HVR-H3 comprising DSNYGEAYAMDY.

6. The anti-Bv8 antibody of claim 5, wherein HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 55, 61, 67, 73, 79, 85, 91, 97, 103, 109, 115, 121, 127, 133, 139, 145 and 151, HVR-L2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 56, 62, 68, 74, 80, 86, 92, 98, 104, 110, 116, 122, 128, 134, 140, 146 and 152, HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 57, 63, 69, 75, 81, 87, 93, 99, 105, 111, 117, 123, 129, 135, 141, 147 and 153, HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 58, 64, 70, 76, 82, 88, 94, 100, 106, 112, 118, 124, 130, 136, 142, 148 and 154, HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 59, 65, 71, 77, 83, 89, 95, 101, 107, 113, 119, 125, 131, 137, 143, 149 and 155, and HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 60, 66, 72, 78, 84, 90, 96, 102, 108, 114, 120, 126, 132, 138, 144, 150 and 156.

7. The anti-Bv8 antibody of any one of claims 1 to 6, wherein the antibody comprises:
(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:61;
(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:62;
(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:63;
(4) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:64;
(5) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:65; and
(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:66.

8. The anti-Bv8 antibody of any one of claims 1 to 6, wherein the antibody comprises:
(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:85;
(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:86;
(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:87;
(4) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:88;
(5) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:89; and
(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:90.

9. The anti-Bv8 antibody of any one of claims 1 to 6, wherein the antibody comprises:
(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:91;
(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:92;
(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:93;
(4) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:94;

(5) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:95; and

(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:96.

10. The anti-Bv8 antibody of any one of claims 1 to 6, wherein the antibody comprises:

(1) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:121;

(2) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:122;

(3) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:123;

(4) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:124;

(5) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:125; and

(6) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:126.

11. The anti-Bv8 antibody of any one of claims 1 to 10 further comprising human VL kappa subgroup IV consensus framework sequence SEQ ID NO:240 and human VH subgroup I consensus framework sequence SEQ ID NO:241.

12. The anti-Bv8 antibody of any one of claims 1 to 6 comprising a light chain variable domain comprising SEQ ID NO:7 and the heavy chain variable domain comprising SEQ ID NO:8.

13. The anti-Bv8 antibody of any one of claims 1 to 6 comprising a light chain variable domain comprising SEQ ID NO:9 and the heavy chain variable domain comprising SEQ ID NO:10.

14. The anti-Bv8 antibody of any one of claims 1 to 6 comprising a light chain variable domain comprising SEQ ID NO:11 and the heavy chain variable domain comprising SEQ ID NO:12.

15. The anti-Bv8 antibody of any one of claims 1 to 6 comprising a light chain variable domain comprising SEQ ID NO:13 and the heavy chain variable domain comprising SEQ ID NO:14.

16. The anti-Bv8 antibody of any one of claims 1 to 15, wherein the anti-Bv8 antibody binds to human Bv8 with Kd values of less than about 0.02 nM.

17. The anti-Bv8 antibody any one of claims 1 to 15, wherein the anti-Bv8 antibody binds to human Bv8 at least two fold tighter than the chimeric 2G9 anti-Bv8 antibody.

18. An antibody that binds to Bv8 or a fragment thereof is provided, wherein the antibody comprises a variable domain comprising the following six HVR sequences:

(i) HVR-L1 comprising SASS X_1VFYMH, wherein X_1 is P or S;

(ii) HVR-L2 comprising DTSX$_1$LAS, wherein X_1 is K or N;

(iii) HVR-L3 comprising QQWS $X_1X_2PX_3T$, wherein X_1 is F, S, W or Y; X_2 is D or E; X_3 is I, L or M;

(iv) HVR-H1 comprising $GFX_1X_2STX_3GMGVS$, wherein X_1 is L or Y; X_2 is I or L; X_3 is P or S;

(v) HVR-H2 comprising HIYWDDDTRYNPSLKS, and

(vi) HVR-H3 comprising RDHGYYWFDY.

19. The anti-Bv8 antibody of claim 18, wherein HVR-L1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:169, 175, 181, 187 and 193, HVR-L2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:170, 176, 182, 188 and 194, HVR-L3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:171, 177, 183, 189 and 195, HVR-H1 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:172, 178, 184, 190 and 196, HVR-H2 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:173, 179, 185, 191 and 197, and HVR-H3 comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:174, 180, 186, 192 and 198.

20. A nucleic acid encoding the antibody of any one of claims 1-19.

21. A vector comprising the nucleic acid of claim 20.

22. The vector of claim 21, wherein the vector is an expression vector.

23. A host cell comprising the vector of claim 21 or 22.

24. A composition comprising the antibody of any one of claims 1-19.

25. The composition of claim 24, wherein the composition comprises a carrier.

26. The composition of claim 24 or 25, which is a pharmaceutical composition.

27. A method for making an anti-Bv8 antibody, said method comprising (a) expressing the vector of claim 21 or 22 in a suitable host cell, and (b) recovering the antibody.

28. The method of claim 27, wherein the host cell is prokaryotic.

29. The method of claim 27, wherein the host cell is eukaryotic.

30. Use of an anti-Bv8 antibody of any one of claims 1-19 in the manufacture of a medicament for treating a tumor, a cancer, or a cell proliferative disorder.

31. The use of claim 30, wherein the cancer is selected from the group consisting of breast cancer, colorectal cancer, lung cancer, renal cancer, glioblastoma, esophageal cancer, melanoma, bladder cancer, ovarian cancer, pancreatic cancer, and hepatocellular carcinoma.

32. The use of claim 31 wherein the cancer is breast cancer, colorectal cancer, lung cancer, renal cancer, ovarian cancer or glioblastoma.

33. Use of anti-Bv8 antibody of any one of claims 1-19 in the manufacture of a medicament for reducing or inhibiting angiogenesis in a subject having a pathological condition associated with angiogenesis.

34. The use of claim 33, wherein said pathological condition is a neoplastic condition.

35. Use of the antibody of any one of claims 1-19 in the manufacture of a medicament for inhibiting endothelial cell proliferation.

36. The use of any of claims 30-35, wherein the subject is to be administered an effective amount of a second medicament, wherein the anti-Bv8 antibody is the first medicament.

37. The use of claim 36, wherein the second medicament is another antibody, a chemotherapeutic agent, a cytotoxic agent, an anti-angiogenic agent, an immunosuppressive agent, a prodrug, a cytokine, a cytokine antagonist, cytotoxic radiotherapy, a corticosteroid, an anti-emetic, a cancer vaccine, an analgesic, or a growth-inhibitory agent.

38. The use of claim 37, wherein the second medicament is an anti-angiogenic agent.

39. The use of claim 38, wherein the anti-angiogenic agent is an anti-VEGF antibody.

40. The use of claim 39, wherein the anti-VEGF antibody is bevacizumab.

41. The use of any one of claims 36-40, wherein the second medicament is to be administered prior to or subsequent to the administration of the anti-Bv8 antibody.

42. The use of any one of claims 36-40, wherein the second medicament is to be administered concurrently with the anti-Bv8 antibody.

43. The use of any of claims 30-40, wherein the subject is to be administered an effective amount of a chemotherapeutic agent.